- US-listed companies
- Citius Pharmaceuticals, Inc.
- Income statement
Citius Pharmaceuticals, Inc.CTXR
Market cap
$10.7M
P/E ratio
| 2011/09 | 2012/09 | 2013/09 | 2015/09 | 2016/09 | 2017/09 | 2018/09 | 2019/09 | 2020/09 | 2021/09 | 2022/09 | 2023/09 | 2024/09 | |
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & development | - | - | - | 2 | 3 | 3 | 7 | 9 | 9 | 12 | 18 | 15 | 12 |
| Operating margin (%) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating income | -25,637 | -19,618 | -28,118 | -3,229,929 | -7,449,291 | -9,986,311 | -13,789,143 | -15,598,361 | -17,710,685 | -23,531,894 | -33,316,045 | -36,732,018 | -41,995,681 |
| Operating expenses | 41,137 | 60,755 | 88,873 | 3 | 7 | 10 | 14 | 16 | 18 | 24 | 33 | 37 | 42 |
| Income before tax | -26,341 | -22,006 | -31,369 | -2,902,268 | -8,295,698 | -10,384,953 | -12,536,638 | 16 | -17,548,085 | - | -33,064,646 | -31,966,912 | -38,849,839 |
| Pretax margin (%) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Provision for income taxes | - | - | - | - | - | - | - | - | - | - | 576,000 | 576,000 | 576,000 |
| Effective tax rate (%) | - | - | - | - | - | - | - | - | - | - | |||
| Net income | -26,341 | -22,006 | -31,369 | -2,902,268 | -8,295,698 | -10,384,953 | -12,536,638 | -15,562,144 | -17,548,085 | -23,054,434 | -33,640,646 | -32,542,912 | -39,425,839 |
| Net income margin (%) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings per share | - | - | - | - | - | - | - | - | - | - | -0.23 | - | -5.97 |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.23 | - | -5.97 |
| Dividend per share | - | - | - | - | 0.6 | - | - | - | - | - | - | - | - |